Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 13/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR1F | P30939 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093572 | 0.95 | UTS2R (0.49) | UTS2RTSHRHTR6MEN1KMT2A | |
| SCHEMBL6839473 | 0.92 | UTS2R (0.45) | UTS2RHTR2CMEN1KMT2APOLB | |
| SCHEMBL6094519 | 0.87 | HRH3 (0.42) | UTS2RTSHRMEN1KMT2A | |
| SCHEMBL6097930 | 0.87 | UTS2R (0.41) | UTS2RMEN1KMT2APOLB | |
| SCHEMBL6608407 | 0.86 | UTS2R (0.64) | UTS2RHTR1ACYP2D6DRD2HTR1D | |
| SCHEMBL6093548 | 0.84 | UTS2R (0.39) | UTS2RTSHRKMT2A | |
| SCHEMBL6742628 | 0.83 | UTS2R (0.70) | UTS2RHTR1ACYP2D6DRD2HTR1D | |
| SCHEMBL6744784 | 0.83 | UTS2R (0.70) | UTS2RHTR1ACYP2D6DRD2HTR1D | |
| SCHEMBL6096149 | 0.83 | UTS2R (0.50) | UTS2RTSHRHTR1ACYP2D6DRD2 | |
| SCHEMBL6609118 | 0.81 | UTS2R (0.65) | UTS2RHTR1ACYP2D6DRD2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019008-B2 | Pyrrolidine sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-28 | — | — | US | claimed |
| US-20050197345-A1 | urotensin II receptor antagonists; cardiovascular disorders; vasodilating agents; Benzo[b]thiophene-2-carboxylic acid [(S)-1-(2-{4-[3-chloro-4-(piperidin-4-yloxy)-benzenesulfonyl]-piperazin-1-yl}-ethylcarbamoyl)-3-methyl-butyl]- | SMITHKLINE BEECHAM CORPORATION | 2005-09-08 | — | — | US | claimed |
| US-20040138224-A1 | Pyrrolidine sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-07-15 | — | — | US | claimed |
| US-20040138224-A1 | Pyrrolidine sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138224-A1 | Pyrrolidine sulfonamides | UTS2R, PRSS2, PRSS8 | UTS2R 1/4885TSHR 1477/4885HTR1A 3467/4885 |
| US-20050197345-A1 | urotensin II receptor antagonists; cardiovascular disorders; vasodilating agents; Benzo[b]thiophene-2-carboxylic acid [(S)-1-(2-{4-[3-chloro-4-(piperidin-4-yloxy)-benzenesulfonyl]-piperazin-1-yl}-ethylcarbamoyl)-3-methyl-butyl]- | UTS2R, PLAUR, NTSR2 | UTS2R 1/4885TSHR 680/4885HTR1A 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.